Navigation Links
Cephalon Signs Option Agreement to Acquire BioAssets Development Corporation
Date:10/26/2009

ted in Maisons-Alfort, France, just outside of Paris. Key affiliates are located in England, Ireland, France, Germany, Italy, Spain, the Netherlands for the Benelux countries, and Poland for Eastern and Central European countries. Cephalon Europe markets more than 30 products in four areas: central nervous system, pain, primary care and oncology.

The company's proprietary products in the United States include: NUVIGIL® (armodafinil) Tablets [C-IV], TREANDA® (bendamustine hydrochloride) for Injection, AMRIX® (cyclobenzaprine hydrochloride extended-release capsules), FENTORA® (fentanyl buccal tablet) [C-II], TRISENOX® (arsenic trioxide) injection, GABITRIL® (tiagabine hydrochloride), PROVIGIL® (modafinil) Tablets [C-IV], and ACTIQ® (oral transmucosal fentanyl citrate) (C-II). The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at http://www.cephalon.com or by calling 1-800-896-5855.

About BioAssets Development Corporation

BioAssets Development Corporation is a private company pioneering novel spine indications for emerging and marketed biologic drugs. The Company's lead initiative focuses on the development of a TNF inhibitor therapy to treat the underlying cause of pain in sciatica. For more information, visit www.biodevco.com.

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding whether Cephalon ultimately will acquire BDC, anticipated scientific progress on its research programs, development of potential pharmaceutical products such as an anti-TNF reactor agent, the relative value to Ceph
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkins Lymphoma
3. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
4. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
5. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
6. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
7. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
8. Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
9. Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
10. Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder
11. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... UBM Medica US announces that  ... help oncologists and other clinicians gain a better understanding ... targeted therapies and immunotherapies, discusses some of the latest ... Every September, Blood Cancer Awareness Month ... blood cancers—helping to increase survival rates and improve the ...
(Date:9/19/2014)... WALTHAM, Mass. , Sept. 19, 2014  Alere ... in rapid diagnostics, issued the following statement today in ... Combating Antibiotic-Resistant Bacteria. "As the global leader ... President for establishing a national strategy to address the ... continuing to work with the Administration on initiatives to ...
(Date:9/19/2014)... Fla. , Sept. 19, 2014  The body ... with the publication of two papers this past week.  ... – Head and Neck Surgery , finds that ... and subjective measures of sleep disordered breathing, leading the ... reduction in obstructive sleep apnea severity and improvement of ...
Breaking Medicine Technology:OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4
... Scripts (Nasdaq: ESRX ), one of the largest ... intention to release its third quarter earnings on Tuesday, October ... quarterly conference call to discuss third quarter results on Wednesday, ... Central Time). This call is being webcast and ...
... ERT ) announced today that it will release ... 27, after the market closes.  After the release, the Company ... day. For the conference call, interested participants ... 1-412-858-4600 when calling internationally. There will be a playback available ...
Cached Medicine Technology:ERT Reports Third Quarter 2011 Operating Results on October 27, 2011 2
(Date:9/21/2014)... SUNDAY, Sept. 21, 2014 (HealthDay News) -- Young women ... and know which foods they should eat. But they ... nutritional choices, according to a new study. ... the University of Illinois,s Peer Education Exercising and Eating ... what would they choose to eat if they were ...
(Date:9/21/2014)... Originally approved by the Food and ... propionate) is a synthetic ICS therapy with potent ... treatment of asthma prophylactically in children and adults. ... and HFA, which received the FDA approval in ... propionate, can bind to glucocorticoid receptors with high ...
(Date:9/21/2014)... 2014 High in the rugged Gore ... and able-bodied athletes rafted the Colorado River, rode mountain ... in pursuit of outdoor adventure. At the September 12-14 ... T.E.A.M. Sports, disabilities proved to be no more than ... three stage event. , Each participating team of five ...
(Date:9/21/2014)... September 21, 2014 “Cluster headaches are ... intense and difficult to resolve,” said Steve Young of ... think of a pain that is more intense.” , ... from cluster headaches, or migraines, that medical research is ... serotonin system,” he added. , Serotonin (5-HT, 5-hydroxytryptamine) is ...
(Date:9/21/2014)... Owings Mills, Md. (PRWEB) September 21, 2014 ... K-12 school with a coed preschool in Owings Mills, Md., ... toward wellness with Garmin Vivofit bands. GFS is the first ... like steps taken, calories burned and even sleep patterns— as ... , a Baltimore area running and walking specialty chain. The ...
Breaking Medicine News(10 mins):Health News: College Women Can Use Food Strategies, Study Finds 2Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News:Disabled Athletes Excel at World T.E.A.M. Sports’ Adventure Team Challenge 2Health News:Disabled Athletes Excel at World T.E.A.M. Sports’ Adventure Team Challenge 3Health News:Homeostasis: Equinox Serotonin (5HT) Headache Stories ~ New on the Bryan William Brickner Blog 2Health News:Garrison Forest School Leader in Independent School Wellness Programs 2
... the risk, experts say , SUNDAY, Aug. 26 (HealthDay News) ... in many parts of the United States, can bring misery ... (hay fever). , Symptoms such as sneezing, runny noses, swollen, ... person,s ability to function normally at work or school, says ...
... multiple auras had seizures arising from one part of brain ... who experience multiple types of auras may be good candidates ... area of the brain, a U.S. study suggests. , The ... , ,included 31 epilepsy patients who experienced multiple types of ...
... teens, the beginning of a new school year is just ... the books again after a three-month-long summer break, but many ... research is emerging that sheds light on a serious problem ... are considered obese is rising dramatically. According to the ...
... , FRIDAY, Aug. 24 (HealthDay News) -- Fish oil ... patients, a U.S. study finds. , Omega-3 fatty acids ... affect blood proteins called matrix metalloproteinase-9 (MMP-9) produced by ... study was conducted by researchers at the Oregon Health ...
... to certain sounds to attract, coax infants, study finds ... with their infants, female rhesus monkeys use special vocalizations ... to get an infant,s attention, University of Chicago researchers ... form of speech, which may be biological in origin," ...
... DALLAS Aug. 23, 2007 The worlds fattest ... thanks to a glut of a key hormone, a ... are diabetic, a UT Southwestern Medical Center researcher has ... and diabetes. But in a multicenter study appearing online ...
Cached Medicine News:Health News:Ragweed Season Doesn't Mean Suffering 2Health News:Some Epilepsy Patients Are Good Candidates for Surgery 2Health News:AASM encourages those student-athletes at risk for developing osa to visit a sleep clinic 2Health News:AASM encourages those student-athletes at risk for developing osa to visit a sleep clinic 3Health News:AASM encourages those student-athletes at risk for developing osa to visit a sleep clinic 4Health News:Monkey Moms Use Baby Talk, Too 2Health News:Despite overeating, morbidly obese mice gain protection against diabetes 2
... The pause of a heartbeat. The ... of rhythmic breathing. These vital signs are ... check. DeRoyals line of Temperature Monitoring products ... the information needed to provide the most ...
... pause of a heartbeat. The bodys warmth ... breathing. These vital signs are yours to ... line of Temperature Monitoring products helps you ... needed to provide the most comfortable and ...
... is a portable, compact, lightweight system with ... emitting the same intensity (50 mW/cm) of ... smaller treatment area (30 cm). Excilite- possesses ... satisfy the most demanding professional users. The ...
... Smart 1064 is a laser system with ... versions with maximum continuous intensities of either 60 ... valid ally in all-mini-invasive surgical techniques. This laser ... it is the most requested from hospitals and ...
Medicine Products: